# EIK1004

Source: https://onco.cc/drugs/eik1004/  
OnCo record `eik1004` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

EIK1004 is an experimental pill being studied to block a DNA-repair enzyme in cancer cells.

## Summary

PARP1-selective inhibitor, also called IMP1707. The sponsor describes CNS penetration as a development feature. The linked registry records distinguish recruiting, closed, and discontinued studies; those states do not establish comparative efficacy or approval.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-10-06
- Also known as: IMP1707
- Modality: Small-molecule PARP1 inhibitor
- Mechanism: PARP1-selective inhibitor, also called IMP1707. The sponsor describes CNS penetration as a development feature.

## Sources

- ClinicalTrials.gov NCT06907043: https://clinicaltrials.gov/study/NCT06907043
- Primary EIK1004 clinical abstract: https://doi.org/10.1158/1538-7445.am2026-ct287

## Connected records

- targets: [PARP](https://onco.cc/targets/parp/)
- trials: [A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.](https://onco.cc/trials/nct06907043/)

---
JSON: https://onco.cc/api/v1/entities/eik1004.json